NCT02086175View on ClinicalTrials.gov

A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

July 11, 2019

Study Completion Date

February 1, 2021

Conditions
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
Interventions
DRUG

Imprime PGG

DRUG

Rituximab

Trial Locations (1)

02115

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

HiberCell, Inc.
All Listed Sponsors
collaborator

HiberCell, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER